Login / Signup
Industries
Technology
Energy
Media
Finance
Green Issues
China
All Concepts
Metals
Energy
Meats
Grains
Softs
ETFs
Indices
Currencies
Geographies
Exchanges
Rates
How To Invest
Personal Finance
Options 101
Definitions
close
close
Send us Feedback
Merck (MRK)
SUMMARY
BULLS
BEARS
TOPICS
DATA CENTRAL
STOCK CHART
OPERATING METRICS
REVENUE SOURCES
SEC FILINGS
BALANCE
INCOME
CASH FLOW
Key Metrics for MRK as compared to
Top Competitors
Drug Manufacturers - Major
Drug Manufacturers*
Drug Manufacturers - Major*
New York Stock Exchange
Pharma & Healthcare
All values TTM unless otherwise noted (*)
INCOME STATEMENT (
See all
)
Revenue
►
23.4B
AVG
EBITDA
►
12.2B
AVG
Net Income
►
8.08B
HIGH
Revenue Growth
►
-2.9%
AVG
Net Income Growth
►
78.3%
HIGH
Operating Margin
►
28.7%
AVG
Net Margin
►
34.6%
AVG
Revenue, Net Income, and Net Margin
Revenue, Gross Profit, and Gross Margin
Operating Income
Ebit
Income Before Taxes
Net Income from Continuing Ops
Interest vs Continuing Income
Interest Coverage
Operating Expenses
Research & Development
SG&A
Amortization & Depreciation
BALANCE SHEET (most recent quarter) (
See all
)
Debt / Equity
►
1.13
AVG
Current Ratio
►
3.70
AVG
Quick Ratio
►
3.44
HIGH
Interest Coverage Ratio
►
58.4
HIGH
Book Value Per Share
►
10.9
Cash Per Share
►
10.3
Loading...
INDUSTRY METRICS (
See all
)
Revenue
►
23.4B
AVG
R&D Expense
►
4.81B
AVG
R&D/Sales Ratio
►
20.1%
HIGH
Expiring Patents
►
7.00
HIGH
Number of Drug Approvals
►
1.00
LOW
Drug Applications
►
2.00
VERY LOW
Number of Drugs in Phase I
►
22.0
AVG
Revenue
Net Income
Operating Income
SEC FILINGS (
See all
)
10-K (Feb 09)
Older:
02/28/08
,
02/28/07
,
03/13/06
,
03/11/05
10-Q (Oct 09)
Older:
08/03/09
,
05/04/09
,
11/03/08
,
07/31/08
8-K (Nov 09)
Older:
10/22/09
,
09/21/09
,
07/31/09
,
07/21/09
Form 4 (Dec 09)
Older:
12/17/09
,
Form 3 (12/16/09)
,
11/16/09
,
11/09/09
View All Filings for Merck (MRK)
STOCK SUMMARY
Open
Day Range
-
52 Week Range
-
Volume
Avg Volume (3 mo)
Shares Outstanding
Market Cap
EPS
1.02
VALUATION
Price to Earnings (P/E)
►
10.3
AVG
Price to Book (P/B)
►
3.63
AVG
Price to Sales (P/S)
►
3.56
AVG
Return on Assets (ROA)
►
17%
AVG
Return on Equity (ROE)
►
38.1%
AVG
EV/EBITDA
►
9.31
AVG
Dividend Yield
3.9%
HIGH
ANALYST RECOMMENDATIONS
OWNERSHIP
Net Insider Buying 3mo
0%
Net Insider Buying 6mo
0%
Net Insider Buying 1yr
0%
Held by insiders
0.1%
Held by institutions
16.3%